BRUSSELS, Nov 29 (Reuters) - Shares in Belgian drugs and chemicals company Solvay (SOLBt.BR: Quote, Profile, Research) and Denmark’s Lundbeck (LUN.CO: Quote, Profile, Research) dived on Tuesday after the companies said the European launch of their bifeprunox drug to treat psychosis would be delayed.
